After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug – AZD5004 – looks like it trails Eli Lilly’s (LLY) oral small molecule orforglipron’s profile and will be three years later to market. Looking at the body of data for weight loss, safety/tolerability and half-life, the firm reiterates its view that “5004’s differentiation (if any) looks too little and too late vs Orforg,” adds the analyst, who keeps a Buy rating and $1,015 price target on Eli Lilly shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- AstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports
- Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank
- 3 Best Stocks to Buy Now, 11/4/2024, According to Top Analysts
- Viking Therapeutics surges after presenting ‘promising’ obesity drug data
- Eli Lilly earnings selloff brings buying opportunity, says JPMorgan